Analysis of the results of the combined method of treatment for colorectal cancer metastases to the liver
Science Articles / / August 12, 2017
LS Frolov, MV Shaydorov
treatment of colorectal cancer (CRC) with liver metastases remains a major unsolved clinical problem.The incidence of colorectal cancer in Russia in 2000 reached 14.81 per 100,000 population.In Togliatti over the past 10 years, this figure has increased by almost 2-fold, from 8.24 to 15.96 per 100,000 people.One of the main causes of death are on the liver metastases at the CRC.Currently, it is an accepted use of combination treatment.The objective of this work was to study the results of the combined (surgical and drug) treatment of patients with colorectal cancer with liver metastases.Group follow-up of 27 people (men - 6 women - 21) between the ages of 40 and 65 with solitary and multiple liver metastases.18 metastasis - of the colon, 9 - from a straight line.Diagnosis was based on data from clinical symptoms of the primary tumor and liver tumors.In the preoperative period was performed ultrasound, CT, MRI, laparoscopy.Morphologically verified diagnosis in 100% of cases.A
All patients received chemotherapy.The unit accounted for 33% of metastases, multiple - 67%.We used the following modes PCTs: 5- FU + leucovorin, Campto + 5- FU + leucovorin, ELOXATIN + 5- FU + leucovorin, monotherapy with Campto and ELOXATIN.
All patients after removal of solitary metastases survived longer than 12 months.Three years lived 9 patients (33%).The average life expectancy in patients treated with adjuvant 5- FU was 12 months.In patients who underwent therapy for schemes with Campto and ELOXATIN life expectancy was significantly higher and amounted to 18 months.Thus, the combined treatment of colorectal cancer with liver metastases is an effective method to increase the survival rate of such patients.The use of modern chemotherapy drugs (Campto, Eloxatin) resulted in a significant increase in the average duration and quality of life.
12 Aug, 2017
12 Aug, 2017